AB0463 THE IMPACT OF PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE (PRAC) RECOMMENDATIONS ON THE REAL-LIFE USE OF JANUS KINASES INHIBITORS FOR RHEUMATOID ARTHRITIS | Publicación